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 ABSTRACT
Calcific Uraemic Arteriolopathy (CUA) or calciphylaxis, is a thrombotic disorder of skin and subcutaneous tissue 
which typically presents with painful purpuric nodules that may progress to necrotic ulcers, and is a severe, life-
-threatening condition. CUA is an uncommon clinical entity that affects mostly haemodialysis (HD) patients. 
Although the process of vascular calcification was initially thought to be the result of a passive deposition of 
calcium -phosphate crystals, current knowledge suggests a distinct mechanism, including cellular activity with 
differentiation of vascular smooth muscle cells (VSMCs) into chondrocyte as well as osteoblast -like cellular phe-
notypes and deficiencies in calcification inhibitors. Although multiple studies suggest a potential relationship 
between warfarin and CUA, larger prospective studies are needed in order to better evaluate this association, 
and randomised controlled trials are needed to assess the benefit of distinct interventions in this setting. In this 
article the topic of CUA is reviewed based on a clinical case of a 65 -year -old man undergoing haemodialysis, who 
underwent an aortic valve replacement one year earlier, receiving a mechanical heart valve, and who has been 
under warfarin therapy since then.
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 INTRODUCTION
Calcific Uraemic Arteriolopathy (CUA), also known 
as calciphylaxis, is a severely morbid and life -threatening 
condition. It is characterised by medial vascular calci-
fication, affecting small arterioles, and results in ischae-
mic subcutaneous necrosis with vulnerable skin 
ulcerations.1
Despite being rare, it is increasingly identified and 
reported worldwide.2
CUA usually occurs in patients with chronic kidney 
disease (CKD), mostly in advanced stages of kidney 
disease (ESRD).
We report a case of calciphylaxis occurring after 
starting warfarin therapy.
 CASE SUMMARY
We report the case of a 65 -year -old male gender 
patient with end -stage renal disease (ESRD) due to 
diabetes mellitus type 2, who had been on haemodi-
alysis for the last 6 years. The patient had a body mass 
index of 25 Kg/m2, and had recently switched to hae-
modiafiltration with a dialysate composition of 1.50 
mmol/L of calcium, 0.50 mmol/L of magnesium and 32 
mmol/L of bicarbonate. The patient underwent an 
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aortic valve replacement one year earlier, receiving a 
mechanical heart valve, and he has been under warfarin 
therapy since then. Secondary hyperparathyroidism 
was not a major problem, as the patient maintained 
serum parathormone levels in the range of 200 to 400 
pg/mL for the last few years (Table I) taking sevelamer 
1600mg/day and cinacalcet 90mg/week.
On February 2014, the patient was referred to the 
Nephrology department due to a painful violaceous 
lesion of 3 cm diameter on the dorsal region of the 
right leg.
A diagnosis of CUA was considered. The frequency 
of haemodialysis sessions was increased to 5 per week 
(4 hours x 5 /week); the dialysate’s calcium was reduced 
to 1.25 mmol/L, and warfarin was stopped and replaced 
by low molecular weight heparin (1mg/Kg/day). Sodium 
thiosulfate (STS) therapy was initiated the first day of 
hospital stay, which was one week after the onset of 
the clinical picture. The patient received STS treatment 
3 x /week at the end of dialysis session, at a 25g dose 
with no side -effects.
Mineral metabolism parameters (Table 1), calcium, 
phosphorus and parathormone levels were within 
acceptable limits. Hand and foot X -rays confirmed ecto-
pic calcifications (Fig. 1). Blood cultures were negative 
and arterial and venous eco -doppler of lower limbs 
was normal.
On the fourth day of hospital stay, a skin biopsy was 
performed and showed epidermis atrophy with focal 
necrosis as well as vascular calcifications in deep der-
mis. The biopsy, performed in the smallest lesion, had 
a proper healing.
However, despite all therapeutic measures, the skin 
lesion continued to increase in dimension while numer-
ous other identical skin lesions appeared in the region. 
The confluence of these small isolated lesions, which 
subsequently suffered necrosis and non -healing 
ulcerations (Fig. 2 and 3), led, after three months, to 
bilateral above -knee amputation. By that time, STS was 
stopped.
Figure 2
Right leg
 
Figure 1
hands with vascular calcifications
 
Table I
Patient’s mineral metabolism values
Before hospitalisation
During hospitalisation
2009 2010 2011 2012 2013
Calcium X Phosphorus (mg/dL)2 39.6±8.0 39.0±6.0 52.6±1.4 42.1±7.2 52.0±1.1 54.3±10.5
Phosphorus (mg/dL) 4.3±0.8 3.7±1.6 4.1±1.2 4.9±0.3 5.1±0.8 6.0±1.2
Calcium (mg/dl) 8.2±0.2 8.6±0.9 4.1±1.2 8.0±1.9 9.0±0.2 9.1±0.5
Parathormone (ng/mL) 198.9±10.2 450.0±110.0 400.0±90.2 235.1±10.6 225.3±90.8 311.0 
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At two years of follow -up, the patient did not show 
any additional complications and was alive and on 
chronic haemodialysis.
 MINI ‑REVIEW
CUA is estimated to occur in 1% of patients with 
chronic renal failure and 4% of patients undergoing 
haemodialysis2-5 and is associated with a high morbidity 
and a mortality rate of 60% -80%, most commonly 
caused by infectious complications, culminating in sep-
sis and organ failure.2,3
Several risk factors for CUA have been suggested, 
such as female gender, diabetes mellitus, obesity, 
hyperphosphataemia, ESRD with severe secondary 
hyperparathyroidism and the use of warfarin or of 
calcium -based phosphate binders.2,3
The insights into the pathogenesis of vascular calcifi-
cation in CKD have changed significantly. Until recently, 
the process of vascular calcification was thought to be 
merely the result of a passive deposition of calcium-
-phosphate crystal.2,6 However, current evidence sug-
gests it is an active and coordinated process which not 
only involves cellular activity with differentiation of vas-
cular smooth muscle cells (VSMCs) into chondrocytes, 
but that it also encompasses osteoblast -like cellular 
phenotypes and deficiencies in calcification inhibitors. 
This process is initiated by the uraemic milieu, which is 
characterised by the presence of hyperphosphataemia, 
uraemic toxins and reactive oxygen species, although it 
is also associated with a decrease in vascular calcification 
inhibitor proteins.3,4
Fetuin­A/α2 -Heremans Schmid glycoprotein (AHSG), 
a 48 -kDa protein, acts as a negative regulator of soft-
-tissue calcification, and it is synthetised in the liver 
and then secreted into circulation. AHSG acts as a sys-
temic inhibitor of hydroxyapatite synthesis, and is 
reduced in states of renal failure, inflammation and 
patients with CUA.2,4,7,8
Some other important inhibitors of vascular calcifica-
tion are Matrix Gla protein (MGP) and Growth arrest-
-specific gene 6 (Gas -6), assuming special importance 
in patients taking vitamin K antagonists, as both are 
vitamin K dependent proteins (VKDPs).9
MGP, which was first described in 1983 and is an 
84 -amino acid protein produced by bone and VSMCs, 
acts as a local inhibitor of calcification.4,5,10 It binds to 
insoluble calcium salts preventing hydroxyapatite crys-
tals growth and, by blocking osteo -inductive properties 
of bone morphogenic protein -2, inhibits VSMCs from 
differentiating into osteoblast -like phenotypes.3,5,6 
Although studies by Murshed et al. have demonstrated 
that MGP is also produced by the liver, such hepatic 
production does not seem to be protective against 
vascular calcification.5,8 In CKD patients, MGP function 
appears to be impaired.9
Gas -6 plays a double role. On the one hand, Gas -6, 
produced by platelets, promotes thrombus formation 
as it contributes to platelet degranulation and aggrega-
tion, and on the other hand, Gas -6 produced by VSMCs, 
by binding the receptor Axl, stimulates the anti -apoptotic 
protein Bcl -2 and inhibits the proapoptotic protein cas-
pase 3, which allows it to play a protective role against 
vascular injury.5 The exact role of Gas -6 and MGP in 
humans still needs further confirmation studies.
Both Gas -6 and MGP share a common characteristic 
– they are VKDPs as they need to undergo gamma-
-carboxylation, a vitamin K dependent process, in order 
to achieve full biological activity.3,4,9
Warfarin shares a common ring structure with vita-
min K, interfering with vitamin K epoxide reductase 
(VKOR), an enzyme responsible for the reduction of the 
naturally oxidised form of vitamin K, which interrupts 
the recycling of this vitamin and ultimately the neces-
sary gamma -carboxylation of VKDPs.5,8 There are two 
subtypes of vitamin K, vitamin K1, a plant -synthesised 
Figure 3
Right leg with non-healing ulcers
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phylloquinone, needed for hepatic carboxylation of 
coagulation factors which activate them and vitamin 
K2, a family of menaquinones which are important for 
the peripheral gamma -carboxylation of proteins such 
as MGP and Gas -6 produced and locally activated at 
VSMCs.7 Animal and clinical studies support the concept 
that hepatic and peripheral carboxylation have unique 
vitamin K dependence. Vitamin K2 mainly affects periph-
eral carboxylation so that supplementation prevents 
arterial calcification while vitamin K1 mostly affects 
hepatic carboxylation and its supplementation does not 
prevent vascular calcification. Phylloquinone (vitamin 
K1) is found in green leafy vegetables. The exact source 
of vitamin K2 is controversial. Some authors claim that 
it comes either from enterocyte conversion of vitamin 
K1 or from indigenous intestinal bacteria.5 Others state 
fermented food, such as cheese, is the main source of 
menaquinones.6 Despite that, both vitamins K1 and K2 
are absorbed from the small ileum and jejunum and 
both are affected by warfarin use.10
Hepatic carboxylation for coagulation factors’ activa-
tion has priority when compared to peripheral carboxy-
lation of VKDPs. So, the first sign of a low functional 
vitamin K status is the incomplete carboxylation of 
extrahepatic Gla proteins, resulting in desphospho-
-uncarboxylated matrix Gla protein (dp -ucMGP) 
increase. The dp -ucMGP is inversely correlated with 
the amount/function of vitamin K and its levels are 
significantly higher in patients under VKA, among other 
situations. Only further studies may demonstrate its 
value as a risk marker for cardiovascular disease and 
mortality.8 According to recent data, low doses of war-
farin are able to inhibit peripheral carboxylation, while 
they have no effect on hepatic carboxylation.5
Some studies with supplementation of vitamin K have 
been conducted. Spronk et al. found in rodents that 
menaquione -4 inhibited warfarin -induced arterial cal-
cification, while phylloquinone did not.8 In human stud-
ies it has also been shown that menaquinone supple-
mentation decreased dp -ucMGP plasma levels.6,8,9
Many researchers suggest that warfarin usage may 
be a risk factor for the development of CUA by the inhi-
bition of VKDPs. Price et al. have shown that warfarin, 
in doses which inhibit gamma -carboxylation of MGP, 
induces widespread vascular calcification in rodents and 
that its combination with Vitamin D–induced hyper-
phosphataemia exacerbates vascular calcification in 
young growing rats and not in mature ones. Those cal-
cifications occur more often in medium -sized vessels, 
sparing capillaries and veins, and predominantly involve 
the elastic lamellae of the media, sparing the intima. It 
was also reported, by Hayashi et al, that warfarin 
increased the risk of calciphylaxis 10 -fold.3
Booth et al. have shown that subclinical vitamin K 
deficiency (normal coagulation studies but low con-
centrations of vitamin K1) is present in almost 30% of 
dialysis patients, combined with elevated serum phos-
phate levels. Patients with end -stage renal disease show 
an increased risk of vascular calcification associated 
with warfarin use as compared with that of the general 
population, which might be explained by the use of 
vitamin D and diminished MGP levels observed in the 
ESRD population.5
However, these data on the role of Gas -6 and MGP 
have not been confirmed in human studies 5.
The registry of the German section of the Interna-
tional Collaborative Calciphylaxis Network (ICCN) has 
shown that about half of all calciphylaxis patients have 
been treated with vitamin K antagonists before the 
onset of symptoms. Furthermore, a Japanese survey 
among dialysis centres estimated the risk of calciphy-
laxis to be 11 -fold higher in patients under warfarin as 
compared with those patients not under VKA treat-
ment.9 However, these results may be biased by con-
founding by indication due to the observational nature 
of these studies.
Some data suggest that some patients may show an 
increased susceptibility to warfarin, due to genetic 
polymorphism in carboxylation enzymes which leads 
to a wide range of VKDP phenotypes, something that 
may explain why many people under this drug do not 
develop CUA.5
CUA typically presents as firm painful purpuric 
plaques and nodules, surrounded by erythema and 
livedo reticularis. Skin lesions may progress to soft-
-tissue ulceration, necrosis and non -healing ulcera-
tions.2,3 The lower extremities are involved in 90% of 
the cases and are the most frequent site involved, but 
skin lesions can occur in multiple other sites.3
 Skin biopsy usually shows medial calcification and 
intimal hyperplasia of small and medium -sized arteries, 
primarily in dermal and subcutaneous tissues. Inflam-
mation with endovascular fibrosis and microthrombi 
are usually also present.2-4 Nevertheless, the benefit 
of performing a skin biopsy should be weighed against 
the risk of profuse bleeding which is sometimes associ-
ated with a poor healing in CUA.
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Several case reports and small case series have sug-
gested that STS, a cations chelator, may be useful in 
treating calciphylaxis. However, published data has 
shown inconsistent results.2,3,11
Nigwekar et al. studied 172 patients from North 
America undergoing maintenance haemodialysis who 
developed CUA and were treated with STS. They 
observed a clinical improvement in the majority of 
patients as well as a lower 1 -year mortality compared 
with historical data from patients not treated with 
STS.12
However, there is no effective treatment to treat 
this disorder. Suggested treatment usually includes 
several distinct measures such as initiation of non-
-calcium -based phosphate binder, discontinuation of 
calcium -based phosphate binder, initiation of cinacal-
cet, discontinuation of vitamin D compounds, lowering 
of dialysate calcium, discontinuation of warfarin, 
increased frequency of haemodialysis sessions, surgical 
parathyroidectomy, and wound care 12 However, there 
is no proof of benefit of any of these measures.
Randomised controlled trials are needed to better 
understand whether warfarin increases the risk for CUA, 
as well as whether vitamin K2 supplementation and 
other interventions could be therapeutic options in 
order to improve the management of this devastating 
condition. Until that data is available from human trials, 
no definitive answers can be provided on the role of 
warfarin in CUA or on the best treatment for CUA.
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